Prostate cancer (PCa) remains a leading cause of cancer-related deaths among men globally, with metastatic castration-resistant PCa (mCRPC) representing an incurable stage despite sequential therapies including androgen deprivation therapy (ADT), next-generation androgen receptor (AR) inhibitors, taxane chemotherapies, and radioligand therapy (RLT, e.g., 177Lu-PSMA) [1]. The gene discussed is AR; the disease is posterior cortical atrophy.